Sino Biopharmaceutical Limited

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:03 23/05/2024 BST			5-day change	1st Jan Change
2.93 ^HKD	-0.34%		-6.09%	-15.56%

01:17pm	Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma	CI
05-09	Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%	MT

Sino Biopharmaceutical Unit to Buy F-star Therapeutics for $161 Million

June 23, 2022 at 01:07 pm

By Colin Kellaher

Sino Biopharmaceutical Ltd. on Thursday said its invoX Pharma unit has agreed to buy clinical-stage biopharmaceutical company F-star Therapeutics Inc. for about $161 million.

Hong Kong-based Sino Biopharmaceutical said invoX would pay $7.12 a share for F-star, a nearly 79% premium to Wednesday's closing price of $3.98 for the Cambridge, England, company.

The transaction, which accelerates invoX's strategy to build Sino Biopharmaceutical's international biopharmaceutical research-and-development platform outside of China, is slated to close in the second half of the year.

Trading in shares of F-star was halted premarket on Thursday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

06-23-22 0806ET

Latest news about Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma	12:17pm	CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%	05-09	MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China	05-09	CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets	04-30	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules	04-30	CI
Sino Biopharm Completes Phase I Study of Hepatitis B Drug	04-25	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	04-22	MT
Hong Kong shares jump on policy support; China slips	04-22	RE
Hong Kong shares jump 1.5% on policy support; China slips	04-22	RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	04-19	MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	04-18	CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	04-17	MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	04-11	MT
Sino Biopharmaceutical Trustee Repurchases Shares	04-08	MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	04-08	MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	04-08	CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	03-29	MT
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	03-28	CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	03-25	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	03-24	CI
Sino Biopharmaceutical's Developing Two Drugs for MASH	03-15	MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy	03-15	MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	03-15	CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR	03-14	MT

Chart Sino Biopharmaceutical Limited

Duration

Period

More charts

Company Profile

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Sector

Pharmaceuticals

Calendar

10/06/2024 - Final dividend

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.727 CNY

Average target price

4.256 CNY

Spread / Average Target

+56.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SINO BIOPHARMACEUTICAL LIMITED	-15.56%	6.91B
ELI LILLY AND COMPANY	+38.28%	723B
NOVO NORDISK A/S	+34.09%	595B
JOHNSON & JOHNSON	-2.71%	369B
MERCK & CO., INC.	+20.51%	332B
ABBVIE INC.	+2.84%	282B
ASTRAZENECA PLC	+17.08%	244B
NOVARTIS AG	+9.56%	208B
ROCHE HOLDING AG	-4.70%	205B
PFIZER, INC.	+0.92%	168B

Other Pharmaceuticals

Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Sino Biopharmaceutical Unit to Buy F-star Therapeutics for $161 Million

EPS Revisions